Equillium (LSE:0A4D) - Stock Price, News & Analysis

0A4D Stock Overview

A clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. More details

0A4D fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 8.27% per year

Earnings have grown 9% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 28.2% per year for the next 3 years

Has less than 1 year of cash runway

Does not have a meaningful market cap ($28M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Equillium, Inc. Competitors

Arecor Therapeutics

AIM:AREC

UK£28.9m

Theracryf

AIM:TCF

UK£2.3m

Tissue Regenix Group

AIM:TRX

UK£40.6m

Avacta Group

AIM:AVCT

UK£175.6m

Price History & Performance

Summary of all time highs, changes and price drops for Equillium
Historical stock prices
Current Share Price	US$0.69
52 Week High	US$3.12
52 Week Low	US$0.49
Beta	1.83
11 Month Change	-47.77%
3 Month Change	-33.65%
1 Year Change	34.95%
33 Year Change	-87.36%
5 Year Change	n/a
Change since IPO	-87.60%

Recent updates

Shareholder Returns

	0A4D	GB Biotechs	GB Market
7D	0%	1.5%	2.2%
1Y	34.9%	-17.9%	8.8%

Return vs Industry: 0A4D exceeded the UK Biotechs industry which returned -17.9% over the past year.

Return vs Market: 0A4D exceeded the UK Market which returned 8.8% over the past year.

Price Volatility

Is 0A4D's price volatile compared to industry and market?
0A4D volatility
0A4D Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine 0A4D's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	45	Bruce Steel	www.equilliumbio.com

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.

Equillium, Inc. Fundamentals Summary

How do Equillium's earnings and revenue compare to its market cap?
0A4D fundamental statistics
Market cap	US$27.63m
Earnings (TTM)	-US$4.61m
Revenue (TTM)	US$45.91m

0.6x

P/S Ratio

-6.0x

P/E Ratio

Is 0A4D overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A4D income statement (TTM)
Revenue	US$45.91m
Cost of Revenue	US$0
Gross Profit	US$45.91m
Other Expenses	US$50.53m
Earnings	-US$4.61m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.13
Gross Margin	100.00%
Net Profit Margin	-10.05%
Debt/Equity Ratio	0%

How did 0A4D perform over the long term?

See historical performance and comparison

0A4D Stock Overview

Rewards

Risk Analysis

Equillium, Inc. Competitors

AIM:AREC

UK£28.9m

AIM:TCF

UK£2.3m

AIM:TRX

UK£40.6m

AIM:AVCT

UK£175.6m

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.11 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: US$0.013 (vs US$0.097 loss in 2Q 2023)

New major risk - Financial position

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Recent updates

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.11 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: US$0.013 (vs US$0.097 loss in 2Q 2023)

New major risk - Financial position

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

New minor risk - Profitability

Forecast to breakeven in 2024

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Insufficient new directors

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab

Insufficient new directors

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Insufficient new directors

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Equillium, Inc. (NasdaqGM:EQ) completed the acquisition of Bioniz Therapeutics, Inc. from Kevin Green for $330 million.

Equillium Announces Data from Phase 1B Equip Study in Patients with Uncontrolled Asthma

High number of new directors

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

High number of new directors

Equillium, Inc. Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell Microcap Value Index

Equillium Inc Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium Presents Data on Target Engagement and Modulation of Cd6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Forecast to breakeven in 2025

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

Equillium, Inc. Announces Positive Data Supporting the Role of Itolizumab as A Potential Treatment for Acute Graft-Versus-Host Disease

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

Equillium, Inc. Appoints Yu (Katherine) Xu, Ph.D., as A Class II Director

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell 2000 Dynamic Index

Equillium, Inc. Appoints Dolca Thomas as Executive Vice President of Research & Development and Chief Medical Officer, Effective January 11, 2021

Equillium Announces Positive Interim Data of Itolizumab in the First-Line Treatment of Acute Graft-Versus-Host Disease

Equillium, Inc. to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

Shareholder Returns